Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 576-583

  Takizawa, Daichi ^a   Kakizaki, Satoru ^a   Horiguchi, Norio ^a   Yamazaki, Yuichi ^a   Tojima, Hiroki ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; CHOLINE; CONSTITUTIVE ANDROSTANE RECEPTOR; DIETHYLNITROSAMINE; KI 67 ANTIGEN; METHIONINE; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DIET; GENE DELETION; GENE TRANSLOCATION; GENOTOXICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; CELL PROLIFERATION; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; FATTY LIVER; GENES, MYC; HEP G2 CELLS; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METHIONINE; MICE; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79953729060     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq277     Document Type: Article

References (47)

1. Schütte, K. et al. (2009) Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis., 27, 80-92.
2. Aravalli, R.N. et al. (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48, 2047-2063.
3. Cabrera, R. et al. (2010) Review article: management of hepatocellular carcinoma. Aliment. Pharmacol. Ther., 31, 461-476.
4. Siegel, A.B. et al. (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer, 115, 5651-5661.
5. Matteoni, C.A. et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116, 1413-1419.
6. Ratziu, V. et al. (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology, 35, 1485-1493.
7. Pitot, H.C. (1990) Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu. Rev. Pharmacol. Toxicol., 30, 465-500.
8. Dragan, Y.P. et al. (1992) The role of the stages of initiation and promotion in phenotypic diversity during hepatocarcinogenesis in the rat. Carcinogenesis (Lond.), 13, 739-750.
9. Preat, V. et al. (1986) Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichloroethane, butylated hydroxytoluene and nafenopin on rat hepatocarcinogenesis. Carcinogenesis (Lond.), 7, 1025-1028.
10. Mayol, X. et al. (1991) Cell proliferation and tumour promotion by ethinyl estradiol in rat hepatocarcinogenesis. Carcinogenesis (Lond.), 12, 1133-1136.
11. Honkakoski, P. et al. (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell. Biol., 18, 5652-5658.
12. Sueyoshi, T. et al. (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem., 274, 6043-6046.
13. Wei, P. et al. (2000) The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature, 407, 920-923.
14. Huang, W. et al. (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl Acad. Sci. USA, 100, 4156-4161.
15. Baskin-Bey, E.S. et al. (2006) Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology, 44, 252-262.
16. Kodama, S. et al. (2004) Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol., 24, 7931-7940.
17. Moreau, A. et al. (2008) Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm., 5, 35-41.
18. Roth, A. et al. (2008) Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol., 73, 1282-1289.
19. Yamamoto, Y. et al. (2004) The orphan nuclear receptor CAR is essential for liver tumor promotion by phenobarbital in mice. Cancer Res., 64, 7197-7200.
20. Huang, W. et al. (2005) Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol., 19, 1646-1653.
21. Ludwig, J. et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 55, 434-438.
22. Diehl, A.M. et al. (1988) Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology, 95, 1056-1062.
23. Powell, E.E. et al. (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 11, 74-80.
24. Leclercq, I.A. et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest., 105, 1067-1075.
25. Brunt, E.M. (2004) Nonalcoholic steatohepatitis. Semin. Liver Dis., 24, 3-20.
26. Yamazaki, Y. et al. (2007) The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut, 56, 565-574.
27. Velayudham, A. et al. (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology, 49, 989-997.
28. Tomita, K. et al. (2008) Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology, 48, 458-473.
29. Rahman, S.M. et al. (2007) CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology, 45, 1108-1117.
30. Ueda, A. et al. (2002) Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol., 61, 1-6.
31. Frith, C.H. et al. (1979) A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol., 3, 329-351.
32. Klaunig, J.E. et al. (1987) Effect of the age of B6C3F1 mice on phenobarbital promotion of diethylnitrosamine-initiated liver tumors. Toxicol. Appl. Pharmacol., 90, 79-85.
33. Harada, T. et al. (1999) Liver and gallbladder. In Maronpot, R.R., Boorman, G.A. Gaul, B.W. (eds.) Pathology of the Mouse. Cache River Press, Vienna, IL, pp. 119-183.
34. Swales, K. et al. (2005) Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells. J. Biol. Chem., 280, 3458-3466.
35. Blanco-Bose, W.E. et al. (2008) C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology, 48, 1302-1311.
36. Perra, A. et al. (2008) Alpha-lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model. Carcinogenesis, 29, 161-168.
37. Zapisek, W.F. et al. (1992) The onset of oncogene hypomethylation in the livers of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis, 13, 1869-1872.
38. Fullerton, F.R. et al. (1990) The inhibition by methionine and choline of liver carcinoma formation in male C3H mice dosed with diethylnitrosamine and fed phenobarbital. Carcinogenesis, 11, 1301-1305.
39. Calvisi, D.F. et al. (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest., 117, 2713-2722.
40. Lee, H.S. et al. (2009) Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res., 15, 812-820.
41. Dong, B. et al. (2009) Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl Acad. Sci. USA, 106, 18831-18836.
42. Baskin-Bey, E.S. et al. (2007) Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J. Gastroenterol., 13, 5635-5641.
43. Gao, J. et al. (2009) The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem., 284, 25984-25992.
44. Rinella, M.E. et al. (2004) The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol., 40, 47-51.
45. Diwan, B.A. et al. (1986) Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. Carcinogenesis (Lond.), 7, 215-220.
46. Yamazaki, Y. et al. (2008) Interstrain differences in susceptibility to nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol., 23, 276-282.
47. Breuker, C. et al. (2010) Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). Endocrinology, 151, 1653-1661.